However, IM is less effective in the accelerated phase and blastic phases of CML and certain patients develop IM resistance due to the mutation and amplification of the BCR-ABL gene. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.